Nektar Therapeutics
NKTR
195 hedge funds and large institutions have $121M invested in Nektar Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 56 increasing their positions, 66 reducing their positions, and 39 closing their positions.
5,713% more call options, than puts
Call options by funds: $465K | Put options by funds: $8K
2.74% more ownership
Funds ownership: 88.52% → 91.26% (+2.7%)
9% less funds holding
Funds holding: 214 → 195 (-19)
15% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 66
46% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 39
68% less capital invested
Capital invested by funds: $376M → $121M (-$255M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$5.82M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$5.17M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$4.63M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.38M |
| 5 |
Two Sigma Advisers
New York
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$8.42M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.77M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$3.02M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$2.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$1.4M |
NKTR Hedge Fund Activity: Q1 2023 in Review
195 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2023, worth a combined $121M — down 68% from $376M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of NKTR and 21 opened new positions — a net loss of 18 holders — while 66 trimmed existing stakes and 56 added.
The largest buyer was Renaissance Technologies, adding an estimated $5.82M. The largest seller was Primecap Management, cutting an estimated $8.42M.
- 195 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2023, down from 214 in Q4 2022.
- Funds reported $121M of Nektar Therapeutics stock for Q1 2023, down 68% quarter-over-quarter.
- 21 funds opened new Nektar Therapeutics positions in Q1 2023 and 39 closed out, a net change of -18 holders.
- The largest Nektar Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $5.82M added.
- The largest Nektar Therapeutics seller in Q1 2023 was Primecap Management, an estimated $8.42M sold.
Based on aggregated 13F filings for Q1 2023.